Core Viewpoint - Hanyu Pharmaceutical experienced a stock price decline of 2.01% on October 14, with a current price of 20.51 CNY per share and a total market capitalization of 18.115 billion CNY. The company has seen a year-to-date stock price increase of 59.12% but has faced recent declines over the past 5 and 20 trading days [1][2]. Financial Performance - For the first half of 2025, Hanyu Pharmaceutical reported a revenue of 549 million CNY, representing a year-on-year growth of 114.86%. The net profit attributable to shareholders was 145 million CNY, showing a significant increase of 1504.30% [2]. - The company has cumulatively distributed 417 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Shareholder Information - As of June 30, 2025, Hanyu Pharmaceutical had 63,000 shareholders, an increase of 9.95% from the previous period. The average number of circulating shares per shareholder decreased by 3.98% to 11,841 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.6817 million shares, which is a decrease of 386,400 shares compared to the previous period [3]. Market Activity - The stock has seen significant trading activity, with a net outflow of 24.2915 million CNY in principal funds on October 14. Large orders accounted for 21.51% of total buying and 25.74% of total selling [1]. - Hanyu Pharmaceutical has appeared on the "Dragon and Tiger List" once this year, with a net buying amount of 545 million CNY on August 4, representing 18.83% of total trading volume [1]. Industry Classification - Hanyu Pharmaceutical operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and chemical preparations. The company is associated with various concepts, including NMN, peptide drugs, raw materials, and monkeypox [2].

证券代码：300199 证券简称：翰宇药业 公告编号：2025-051 深圳翰宇药业股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或变更议案的情况发生。 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开和出席情况 1、2025年9月25日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰 宇药业"）第六届董事会第七次会议审议通过《关于提请召开2025年第二次临 时 股 东 大 会 的 议 案 》 ， 详 见 公 司 在 中 国 证 监 会 指 定 信 息 披 露 网 站 （http://www.cninfo.com.cn）披露的相关公告。 2025年第二次临时股东大会召开的基本情况如下： 会议召集人：公司董事会 会议方式：本次会议采取现场投票和网络投票相结合的方式 会议召开时间：2025年10月13日（周一）下午15:30 会议地点：深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼会 议室 会议主持人：董事长曾少贵先生 本次会议的召集、召开符合《公司法》《上 ...

法律意见书 国浩律师（深圳）事务所 关于 网址/Website: http://www.grandall.com.cn 二〇二五年十月 深圳翰宇药业股份有限公司 二〇二五年第二次临时股东大会 的 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙 ·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨·乌兹别克斯坦 Hongkong·Paris·Madrid·Silicon ...

1、本次股份解除质押基本情况 2、股东股份累计质押情况 证券代码：300199 证券简称：翰宇药业 公告编号：2025-050 深圳翰宇药业股份有限公司 关于控股股东、实际控制人办理部分股票 解除质押业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份解除质押基本情况 近日，公司接到控股股东、实际控制人曾少贵先生、曾少强先生的通知，曾 少贵先生、曾少强先生办理了部分股票解除质押业务。具体事项如下： | 股东 名称 | 是否为控股 股东或第一 大股东及其 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解除 日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行动人 | （股） | （%） | （%） | | | | | 曾少贵 | 是 | | | | | | 深圳担保集团有 | | | | 12,795,875 | 12.99 | 1.45 | 2024/7/24 | 2025/9/30 | 限公司 | | 曾少贵 ...

Group 1 - On September 30, Hanyu Pharmaceutical's stock increased by 1.52%, with a trading volume of 689 million yuan [1] - The financing data shows that on the same day, Hanyu Pharmaceutical had a financing purchase amount of 70.21 million yuan and a financing repayment of 93.34 million yuan, resulting in a net financing outflow of 23.13 million yuan [1] - As of September 30, the total balance of margin trading for Hanyu Pharmaceutical was 1.291 billion yuan, accounting for 6.85% of its market capitalization, which is above the 80th percentile level over the past year [1] Group 2 - As of June 30, the number of shareholders of Hanyu Pharmaceutical was 63,000, an increase of 9.95% compared to the previous period [2] - For the first half of 2025, Hanyu Pharmaceutical achieved an operating income of 549 million yuan, a year-on-year increase of 114.86%, and a net profit attributable to shareholders of 145 million yuan, a year-on-year increase of 1504.30% [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends distributed in the last three years [2]

Market Overview - The Shanghai Composite Index rose by 0.90% on September 29, with 26 out of 28 sectors experiencing gains, led by non-bank financials and non-ferrous metals, which increased by 3.84% and 3.78% respectively [1] - The pharmaceutical and biological sector saw a modest increase of 0.17% [1] - The coal and banking sectors were the biggest losers, declining by 0.84% and 0.46% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets was 9.527 billion yuan, with 13 sectors receiving net inflows [1] - The non-bank financial sector had the highest net inflow of 12.348 billion yuan, corresponding to its 3.84% increase [1] - The non-ferrous metals sector followed with a net inflow of 2.986 billion yuan and a daily increase of 3.78% [1] - Conversely, 18 sectors experienced net outflows, with the electronics sector leading at a net outflow of 2.811 billion yuan, followed by the defense and military sector with 1.882 billion yuan [1] Pharmaceutical and Biological Sector - The pharmaceutical and biological sector had a net outflow of 1.640 billion yuan, with 285 out of 475 stocks in the sector rising, while 169 fell, including 2 hitting the daily limit down [2] - Notable stocks with significant net inflows included Jilin Aodong (10.565 million yuan), Sino Medical (10.067 million yuan), and Mindray Medical (9.186 million yuan) [2] - Major stocks with significant net outflows included Hengrui Medicine (-333.586 million yuan), Guangsheng Tang (-160.353 million yuan), and Hanyu Pharmaceutical (-138.282 million yuan) [4] Top Gainers in Pharmaceutical Sector - Jilin Aodong saw a price increase of 6.69% with a turnover rate of 4.00% and a net inflow of 10.565 million yuan [2] - Sino Medical increased by 4.82% with a turnover rate of 7.00% and a net inflow of 10.067 million yuan [2] - Mindray Medical had a slight increase of 0.19% with a turnover rate of 0.68% and a net inflow of 9.186 million yuan [2] Top Losers in Pharmaceutical Sector - Hengrui Medicine decreased by 1.26% with a turnover rate of 1.02% and a net outflow of 333.586 million yuan [4] - Guangsheng Tang experienced a decline of 6.18% with a turnover rate of 11.07% and a net outflow of 160.353 million yuan [4] - Hanyu Pharmaceutical had a minor increase of 0.24% but still faced a net outflow of 138.282 million yuan [4]

Core Viewpoint - Hanyu Pharmaceutical is launching a private placement to raise up to 968 million yuan to expand its peptide drug production capacity and enhance its market position, following the successful international launch of its core product [1][2]. Group 1: Fundraising and Investment Plans - The company plans to issue shares to no more than 35 specific investors, with the raised funds allocated to various projects, including peptide drug production line expansion and R&D laboratory upgrades [2][3]. - The total investment for the peptide drug production line and green intelligent expansion project is 549 million yuan, with 495 million yuan from the raised funds, accounting for 51.56% of the total [2]. - The company aims to produce an additional 2000 kg of peptide raw materials annually to meet market demand after the completion of the new production line [2]. Group 2: Financial Performance and International Expansion - Hanyu Pharmaceutical has experienced a turnaround, achieving a net profit of 145 million yuan in the first half of 2025, marking a significant recovery from seven consecutive years of losses [6]. - The company's international business has become a key growth driver, with overseas revenue reaching 425 million yuan in the first half of 2025, a year-on-year increase of 272.76%, accounting for 77.4% of total revenue [6]. - The gross profit margin for international business was 66.51%, significantly higher than the domestic margin of 48.61% [6]. Group 3: Product Development and Market Position - Hanyu Pharmaceutical's liraglutide injection received FDA approval in December 2024, becoming the first generic liraglutide drug in the U.S., which has bolstered its international market presence [1][5]. - The company currently has 29 peptide drugs, 9 new drug certificates, and 31 clinical approvals, with products certified by GMP in multiple regions including the U.S., EU, and South Korea [6].

Core Viewpoint - Han Yu Pharmaceutical (300199) announced that neither the company nor its subsidiaries have any external guarantees outside the scope of the consolidated financial statements, and there are no overdue guarantees [1] Group 1 - The company has confirmed the absence of external guarantees outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company or its subsidiaries [1]

Group 1 - The core point of the article highlights the significant share pledges by major shareholders of Hanyu Pharmaceutical, indicating potential liquidity concerns [1] - As of the announcement date, the cumulative pledged shares by Zeng Shaogui amount to approximately 64.49 million shares, representing 65.45% of his holdings [1] - Zeng Shaoqiang has pledged approximately 37.66 million shares, which is 59.64% of his holdings, while Zeng Shaobin has pledged 8.5 million shares, accounting for 39.14% of his holdings [1] Group 2 - For the first half of 2025, Hanyu Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing sector, with a 100% contribution [1] - The current market capitalization of Hanyu Pharmaceutical is 18.5 billion yuan [1]

截至公告披露日，公司控股股东、实际控制人所持股份质押情况如下： 证券代码：300199 证券简称：翰宇药业 公告编号：2025-049 深圳翰宇药业股份有限公司 关于控股股东、实际控制人办理部分股票 解除质押业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，公司接到控股股东、实际控制人曾少贵先生、曾少强先生、曾少彬先 生的通知，曾少贵先生、曾少强先生、曾少彬先生办理了部分股票解除质押业务。 具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次解除质 | 占其所持 | 占公司总股 | | 解除 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 押股份数量 | 股份比例 （%） | 本比例（%） | 起始日 | 日期 | 质权人 | | | 一致行动人 | （股） | | | | | | | 曾少贵 | 是 | 4,200,000 | 4.26% | 0.48% | 2023/07/27 | 2025/9/26 | 深圳市高新投保 | | | | | ...